Neonatal Sepsis
While significant achievements have been made in reducing mortality in children under the age of five, mortality remains a burden in children less than one month of age with antimicrobial resistance posing a particular threat. The neonatal sepsis programme, which has established two target product profiles, aims to develop:

  • an alternative first-line treatment for clinically diagnosed cases of sepsis (delivered by 2023)
  • a new treatment for confirmed multidrug-resistant pathogens (in clinical development or delivered by 2023)

Read more

Sexually Transmitted Infections
A significant sexually transmitted infection (STI), Neisseria gonorrhoeae is threatening to soon become untreatable due to its resistance to all available classes of antimicrobials. The sexually transmitted infections programme will accelerate the entry of new antibiotics and explore the use of combinations, including old and new antibiotics, while focusing development on specific public health needs (e.g. confirmed drug-resistant, extragenital, and complicated cases of gonorrhoea). This programme, which has established a short- and long-term target product profile, aims to develop:

  • a new treatment for gonorrhoea, including multidrug-resistant cases (delivered by 2023)
  • a combination treatment to be integrated for syndromic management of STIs (in clinical development)

Read more

 

Paediatric Antibiotic Platform
This programme aims to optimize current treatments and accelerate development of pipeline / new antibiotics for children through improvements in dose, duration of treatment, and formulation, or through combinations. Depending on the outputs of the initial scoping exercise to be undertaken over 2017/18, at least two projects are anticipated. This programme aims to develop:

  • an optimized paediatric antibiotic treatment (delivered by 2023)
  • 1-2 additional paediatric projects (in clinical development by 2023)
Exploratory/Upstream/Memory Recovery
Through this early-stage programme, GARDP will explore and support alternative upstream R&D approaches to address gram-negative pathogens that cause serious bacterial infections as well as possibly fungal infections. While directly supporting existing GARDP programmes and/or providing impetus for new ones, it also aims to contribute to the broader antibiotic R&D community.

A key component is the Antimicrobial Memory Recovery Programme which aims to recover and bring together the knowledge, experts, data, and assets of forgotten, abandoned, or withdrawn antibiotics. AMRI will also identify possible pre-clinical and clinical candidates. Additionally, an antibiotic drug combination platform may be developed to optimize regimens consisting of existing/new antibiotics and non-antibiotic drugs. Depending on the number and quality of drug candidates identified, this programme aims to:

  • bring one candidate to lead optimization and one new chemical entity to late-stage clinical development (by 2023)

Read more about the Antimicrobial Memory Recovery Programme